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Abstract 
Renal cell cancer (RCC) accounts for approximately 3% of all adult malignancies. RCC 
has a metastasis rate of approximately 25%, which is most commonly to the lungs 
(>50%). On the contrary, RCC metastasis to the gastrointestinal tract (excluding the liver) 
is very uncommon and ranges from 0.2 to 0.7%. Thus, a gastric cancer in a patient with 
known metastatic RCC would most likely be secondary to metastasis. We present the first 
reported case of a metastatic RCC coexisting with a new-onset primary gastric cancer 
and a review of management using guidelines from metastatic RCC to the stomach. 
An 82-year-old African American male with papillary RCC status post left nephrectomy 
with recurrence of liver metastasis presented with failure to thrive shortly after his third 
cycle of chemotherapy despite stable disease by imaging studies. He had received 
7 chemotherapy cycles of Gemzar, Nexavar, and Avastin prior to admission. He 
subsequently had a drop in his hemoglobin and was found to have hemoccult positive 
stool in the setting of recent Avastin. Endoscopic evaluation showed a 3 cm ulcerated 
mass in the cardia which was biopsied. The biopsy showed invasive and poorly 
differentiated gastric adenocarcinoma unrelated to his RCC. The patient subsequently 
underwent partial gastrectomy with loop gastrojejunostomy for resection of his stage 1 
primary gastric adenocarcioma. The surgery also facilitated future chemotherapy 
(Avastin), which could not be given prior to surgery due to its side effect of bleeding. The 
patient did not receive adjuvant chemoradiation for his gastric cancer due to his 
comorbidities at the time and was doing well at a one month follow-up. Metastatic RCC 
and primary gastric cancer can coexist, especially when there is an overlap of risk factors 
such as smoking or nitrosamines. The management of a gastric cancer in the setting of 
metastatic RCC is similar to the management of solitary primary gastric carcinoma.  
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Treatment of the primary gastric cancer can facilitate future chemotherapy such as 
Avastin, which has been recently approved for the treatment of metastatic RCC. 
Introduction 
Renal cell cancer (RCC) is the most common type of renal tumor and has the highest 
incidence in the sixth decade and in men (2×) [1]. Several risk factors predispose to RCC 
including tobacco smoking, obesity, asbestos, lead phosphate, nitrosamines, and genetic 
syndromes such as von Hippel-Lindau syndrome [1]. On the other hand, gastric 
carcinomas comprise less than 1% of all adult malignancies in the United States, with a 
higher incidence in Japan and Korea [2]. Risk factors for gastric cancer can be divided 
into genetic factors and modifiable risk factors. Genetic factors include pernicious 
anemia, type A blood (weak association), family history of cancer, Li-Fraumeni 
syndrome, and hereditary nonpolyposis coli [2]. Modifiable risk factors include tobacco 
smoking, H. pylori infection, radiation exposure, and dietary factors [2]. Dietary factors 
include high salt, low vitamin A/C intake (low amounts of fruits/vegetables) as well as 
high nitrate intake (salted, pickled, chemically preserved foods). Smoking and 
nitrosamines are the only common risk factors in both RCC and gastric cell cancer. Our 
patient had a remote smoking history as well as asbestos exposure, which were probably 
the risk factors for his RCC. 
To our knowledge, this is the first report describing a patient with metastatic papillary 
RCC to the liver and a primary, localized gastric adenocarcinoma. Interestingly enough, 
the patient presented with failure to thrive in the setting of chemotherapy and 
multifactorial anemia, which was primarily due to his gastric carcinoma. 
Case Report 
An 82-year-old African American male was admitted to our hospital with failure to thrive as defined 
by ECOG performance score 3 with specific complaints of generalized weakness and poor oral intake. 
He had undergone a left radical nephrectomy in 2004 for a grade 3 tumor approximately 4 cm in size 
invading the renal vein and perinephric adipose tissue. He did not receive any adjuvant chemotherapy 
or immunotherapy at the time and was followed up by his urologist. He had no evidence of recurrence 
until November 2008 when he was found to have liver metastasis with an 11 mm lesion and a 2.8 cm 
renal mass. A liver biopsy (fig. 1) showed metastatic papillary RCC and the patient was initiated on 
chemotherapy with Gemzar, Nexavar, and Avastin (7 cycles) prior to this hospital admission. The 
patient’s metastatic disease looked stable by CT scan. The patient was initially thought to have failure to 
thrive due to catheter-related infection and had an associated leukocytosis of 19,000 cells/l upon 
admission. 
The patient had no evidence of infection, but subsequently his Hct dropped and he was found 
to have a positive hemoccult in the setting of multifactorial anemia, on Procrit. Gastroenterology 
evaluation was warranted since the patient was on Avastin and the proven incidence of bleeding in 
Avastin is approximately 7–9%. Additionally, the patient had no prior history of gastrointestinal (GI) 
bleeding. Although Avastin has been classically associated with nose bleeds and serious hemoptysis in 
patients with lung cancer, workup was initiated for future consideration of chemotherapy. The known 
side effects of Avastin in the GI tract include GI perforation/GI fistulas and there are reports of Avastin 
causing gastric/duodenal ulcers which have sometimes led to life-threatening or fatal bleeding [3]. There 
are also reports of minor GI bleeds that have heralded GI perforation [3]. This is especially important 
considering Avastin decreases angiogenesis and is associated with decreased wound healing, which is 
important in ulcer resolution.  
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The patient had an EGD which showed a 3 cm ulcerated mass in the cardia (fig. 2, fig. 3) which bled 
on contact and was subsequently biopsied (fig. 4). The biopsy showed invasive and poorly differentiated 
gastric adenocarcinoma (fig. 5, fig. 6). H. pylori was negative, which was expected due to the location 
being in the cardia. There has been an increase in gastric cancer in the cardia that has paralleled 
esophageal adenocarcinoma related to Barret’s transformation and the increasing incidence of obesity in 
America [4]. Gastric cancers in the cardia are almost universally H. pylori-negative and there are studies 
in Europe that have shown a decreased incidence of esophageal carcinoma as well as gastric cancer in 
the cardia in patients with H. pylori [4]. Lastly, in the United States, the predominant location of gastric 
cancer is now in the cardia with 31%, which is higher than the antrum with 26% [2]. 
The patient subsequently underwent a partial gastrectomy with loop gastrojejunostomy for resection 
of his stage 1 primary gastric adenocarcioma. He tolerated the procedure without complications and 
had a relatively short postoperative course to recovery. However, he did not receive adjuvant 
chemoradiation for his gastric cancer due to his comorbidities at the time. He did well after his 
discharge at a one month follow-up. 
Discussion 
RCC is known for its propensity to metastasize via both hematogenous mechanisms as 
well as (less commonly) lymphatics [5]. Ritchie and deKernion [5] reported that RCC 
presents with metastatic disease in 23% of cases and that metastasis occurs within 5 years 
of nephrectomy in 25% of cases, which occurred to the liver in our patient. The liver is 
a common site of metastasis for RCC due to the common inferior vena cava drainage of 
the renal vein and the hepatic vein. This is the only case, to our knowledge, of a patient 
with a papillary RCC with metastasis to the liver who also had a primary gastric 
adenocarcinoma. This discussion will cover the literature regarding gastric metastasis 
from RCC and subsequently the local management of primary gastric carcinoma. 
Our patient presented with failure to thrive in the setting of metastatic RCC, which in 
turn led to an earlier diagnosis of primary gastric carcinoma. It is pivotal to diagnose 
gastric cancers prior to spreading, as the cancer is very amenable to surgery and possibly 
endoscopy if in the early stages of the disease. The usual presentation of gastric cancer is 
with early satiety, nausea, vomiting, weight loss, epigastric pain, or iron deficiency anemia 
in the case of ulceration. The presentation depends on the type of gastric cancer. The 
intestinal type of gastric cancer is more likely to present with the aforementioned 
symptoms as it is the result of a chronic inflammatory process. On the other hand, the 
diffuse type of gastric carcinoma is more prevalent in women and in individuals under the 
age of 50. Note that in a patient with a prior history of RCC, there are case studies 
illustrating that surveillance EGD can be performed in the setting of undiagnosed upper 
GI hemorrhage, as it may herald the recurrence of RCC [6]. 
On the other hand, in RCC metastatic to the stomach, metastasis was the presenting 
sign of the cancer in most cases or occurred during follow-up after nephrectomy with a 
mean of 6.6 years, which is later than any other metastasis site [7]. Presenting symptoms 
were mainly upper or lower GI bleeding and rarely anemia [5]. For patients with a 
solitary metastasis and with appropriate ECOG scores, gastrectomy is performed as a 
complementary treatment [8]. For patients with multiple or inoperable metastases, 
treatment consisted of either endoscopic resection, embolization of the metastasis, 
or immunotherapy [8]. The benefit of surgery in terms of survival could not be 
demonstrated due to the short follow-up of 8.6 months [9].  
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Surgical resection of the metastasis has been the preferred treatment in the case of a 
solitary metastasis and absence of contraindication related to the general state [8]. In 
other cases, endoscopic resection or embolization of the metastasis have been proposed, 
with or without systemic immunotherapy. There are numerous cases that confirm the 
potential of RCC for late and solitary metastasis with circumscribed local invasiveness, 
suggesting that endoscopic resection may be feasible [10]. Although recently, endoscopic 
mucosal resections have shown equivocal 5-year survival to surgery for early gastric 
cancer with differentiated tumors that are slightly raised and less than 2 cm in diameter, 
or in differentiated tumors that are ulcerated and less than 1 cm in diameter [2], the role 
of targeted anti-tumor treatments, such as anti-angiogenic drugs, has not been evaluated 
[9]. 
A review of the literature shows that the management of a solitary gastric cancer, 
even in the setting of RCC with metastasis to unadjacent organs, is ideally surgical if the 
tumor is greater than 2 cm [8]. In our patient, the gastric cancer was 3 cm in size without 
nodal involvement, and thus not a candidate for endoscopic mucosal resection. The type 
of surgery performed depends on the extent and location of the tumor; therefore, 
preoperative evaluation is critical. Initial diagnosis may be established by endoscopy with 
biopsy. Endoscopic ultrasound should follow. Endoscopic ultrasound has a sensitivity of 
85% in assessing the depth of tumor invasion and detecting nodal involvement prior to 
surgery [2]. Laparoscopic staging prior to surgical resection is also advocated and has 
impacted preoperative treatment decisions [2]. Lastly, as advocated by previous studies 
mentioned above, in a patient with a history of RCC who presents with failure to thrive 
and anemia, GI metastasis versus a primary tumor in the GI tract should be considered if 
risk factors overlap, especially when there is a history of smoking. 
In conclusion, metastatic RCC and primary gastric cancer can coexist, especially when 
there is an overlap of risk factors such as smoking or nitrosamines. The management of a 
gastric cancer in the setting of metastatic RCC is similar to the management of solitary 
primary gastric carcinoma. Treatment of the primary gastric cancer can facilitate future 
chemotherapy such as Avastin, which has been recently approved for the treatment of 
metastatic RCC. 
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Fig. 1. Photomicrograph of liver biopsy illustrating a metastatic papillary renal cell carcinoma. 
Immunohistochemical staining revealed PAX-2 positivity and Mucin negativity. A PAX-2 positive 
stain is highly specific for RCC. A Mucin negative stain suggests against gastric cell carcinoma. 
 
 
 
Fig. 2. Superior EGD view discovering a 3 cm mass in the gastric cardia. 
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Fig. 3. Horizontal EGD view showing a friable, ulcerated mass with an umbilicated center with central 
depression. 
 
 
 
Fig. 4. On EGD, the mass bled on contact prior to biopsy. 
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Fig. 5. Photomicrograph of EGD biopsy, which showed classic signet ring morphology. 
 
 
 
Fig. 6. Photomicrograph of EGD biopsy is consistent with invasive and poorly differentiated gastric 
cell carcinoma. 
 
References 
1 Diaz JI, Mora LB, Hakam A: The Mainz Classification of renal cell tumors. Cancer Control 1999;6:571–579. 
2 Johns Hopkins Hospital Gastroenterology Department. http://www.hopkins-gi.org/GDL_Disease.aspx? 
CurrentUDV=31&GDL_Disease_ID=DB2F8EAC-4421-41DD-B04E-684AFEF2AD94&GDL_DC_ID= 
E25BDF77-223D-4B6F-9700-5BE41DBDE28B.  
Case Rep Gastroenterol 2010;4:421–428 
DOI: 10.1159/000320871 
Published online: 
October 5, 2010 
© 2010 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
428
3 Tol J, Cats A, Mol L, Koopman M, Bos MM, van der Hoeven JJ, Antonini NF, van Krieken JH, Punt CJ: 
Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New 
Drugs 2008;26:393–397. 
4 Devesa SS, Fraumeni JF Jr: The rising incidence of gastric cardia cancer. J Natl Cancer Inst 1999;91:747–749. 
5 Ritchie AW, deKernion JB: The natural history and clinical features of renal carcinoma. Semin Nephrol 
1987;7:131–139. 
6 Haffner J, Morel JF, Maunoury V, Caty A, Biserte J, Villers A: Gastric or duodenal metastases from clear 
cell renal cell carcinoma. Report of two cases and review of the literature (article in French). Prog Urol 
2007;17:1305–1309. 
7 Matsutani T, Sasajima K, Miyamoto M, Yokoyama T, Maruyama H, Yanagi K, Matsuda A, Kashiwabara M, 
Suzuki S, Tajiri T: Resection of pancreatic metastasis from renal cell carcinoma and an early gastric cancer. 
J Nippon Med Sch 2008;75:41–45. 
8 Thyavihally YB, Mahantshetty U, Chamarajanagar RS, Raibhattanavar SG, Tongaonkar HB: Management of 
renal cell carcinoma with solitary metastasis. World J Surg Oncol 2005;3:48. 
9 Sadler GJ, Anderson MR, Moss MS, Wilson PG: Metastases from renal cell carcinoma presenting as 
gastrointestinal bleeding: two case reports and a review of the literature. BMC Gastroenterol 2007;7:4. 
10 Picchio M, Paioletti A, Santini E, Iacoponi S, Cordahi M: Gastric metastasis from renal cell carcinoma fourteen 
years after radical nephrectomy. Acta Chir Belg 2000;100:228–230. 